Pharmacotherapy – Talk Bio

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

1 week ago talkbio0Tagged BioNTech, BNT327, Burning Mouth Syndrome, Myers, Overall response rate, PD-L1, PD-L1xVEGF, Pharmacotherapy, pumitamig, Small cell carcinoma of lung, squibb, Vascular Endothelial Growth Factor A

BioNTech; Bristol Myers Squibb; BMS; PD-L1xVEGF bispecific; BNT327; pumitamig; small cell lung cancer; SCLC; phase 2 trial; phase 3 dose; overall response rate; VEGF-A; PD-L1; chemotherapy

AstraZeneca Escalates EGFR Lung Cancer Rivalry with J&J: Tagrisso Combo Posts Survival Win

1 week ago talkbio0Tagged AstraZeneca, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, Lazcluze, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Rybrevant, Tagrisso

AstraZeneca; Tagrisso; EGFR-mutated NSCLC; Johnson & Johnson; Rybrevant; Lazcluze; Flaura2 trial; overall survival; lung cancer; chemotherapy combination

ImmuneOnco and Instil Bio’s PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

2 months ago talkbio0Tagged Bio, Combined, Frequency of Responses, IMM2510/AXN-2510, ImmuneOnco, Instill - dosing instruction imperative, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-L1xVEGF, Pharmacotherapy, safety profile

ImmuneOnco; Instil Bio; IMM2510/AXN-2510; PD-L1xVEGF bispecific antibody; NSCLC; Phase 2 clinical trial; response rate; safety profile; chemotherapy combination; lung cancer

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

2 months ago talkbio0Tagged AstraZeneca, Benefit, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, life-extension, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Tagrisso

AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit